NewsZydus Lifesciences Independent Director Apurva S. Diwanji Ceases Post Upon Tenure CompletionZydus Lifesciences Independent Director Apurva S. Diwanji Ceases Post Upon Tenure Completion
Zydus Lifesciences Limited disclosed that Mr. Apurva S. Diwanji (DIN: 00032072) ceased as Director, including Independent Director, effective May 12, 2026, following completion of his tenure. The company filed the requisite disclosure with BSE and NSE on May 13, 2026, and acknowledged Mr. Diwanji's contributions, dedication, and professional expertise during his tenure.
*this image is generated using AI for illustrative purposes only.
Zydus Lifesciences Limited has informed the stock exchanges that Mr. Apurva S. Diwanji (DIN: 00032072) has ceased to serve as Director, including in his capacity as Independent Director, effective Tuesday, May 12, 2026. The cessation follows the completion of his tenure and has been disclosed pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026.
Director Cessation Details
The company filed the requisite disclosure with BSE Limited and the National Stock Exchange of India Limited on May 13, 2026. The key details of the change, as per the SEBI Master Circular, are outlined below:
| Parameter: | Details |
|---|---|
| Name of Director: | Mr. Apurva S. Diwanji (DIN: 00032072) |
| Reason for Cessation: | Ceased as Director (including as Independent Director) consequent upon completion of tenure |
| Date of Cessation: | Effective Tuesday, May 12, 2026 |
| Relationship with Directors/KMP: | Not Applicable |
Company's Acknowledgement
Zydus Lifesciences placed on record its sincere appreciation for the valuable contributions made by Mr. Diwanji during his tenure. The company also expressed gratitude for his dedication, integrity, and professional expertise, which enriched its deliberations and decision-making processes. The disclosure was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on May 13, 2026.
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.58% | +5.63% | +7.51% | +5.04% | +9.96% | +60.69% |
Who is Zydus Lifesciences likely to appoint as the new Independent Director to replace Mr. Apurva S. Diwanji, and what expertise profile will the company prioritize?
How might the departure of Mr. Diwanji affect the composition and independence quorum of Zydus Lifesciences' board committees, particularly the audit and risk committees?
Could this board-level transition influence Zydus Lifesciences' ongoing regulatory approvals, strategic partnerships, or pipeline decisions in the near term?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
